BIO-TECHNE Corp (NASDAQ:TECH) Announces $0.32 Quarterly Dividend

Share on StockTwits

BIO-TECHNE Corp (NASDAQ:TECH) announced a quarterly dividend on Tuesday, October 29th, Fidelity reports. Shareholders of record on Friday, November 8th will be paid a dividend of 0.32 per share by the biotechnology company on Friday, November 22nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date is Thursday, November 7th.

Shares of NASDAQ:TECH traded down $0.76 on Wednesday, reaching $203.94. 695 shares of the company’s stock were exchanged, compared to its average volume of 119,500. The firm has a market capitalization of $7.97 billion, a price-to-earnings ratio of 53.67, a PEG ratio of 4.49 and a beta of 1.22. BIO-TECHNE has a fifty-two week low of $132.75 and a fifty-two week high of $217.15. The business’s 50-day moving average is $201.60 and its two-hundred day moving average is $201.48. The company has a quick ratio of 3.41, a current ratio of 4.44 and a debt-to-equity ratio of 0.47.

BIO-TECHNE (NASDAQ:TECH) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $1.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.14. The company had revenue of $183.24 million for the quarter, compared to analysts’ expectations of $179.38 million. BIO-TECHNE had a net margin of 12.68% and a return on equity of 13.36%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 earnings per share. Analysts predict that BIO-TECHNE will post 4.26 earnings per share for the current fiscal year.

In other news, CEO Charles R. Kummeth acquired 200 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were acquired at an average price of $185.00 per share, with a total value of $37,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.20% of the stock is owned by company insiders.

A number of analysts have weighed in on TECH shares. TheStreet cut shares of BIO-TECHNE from a “b” rating to a “c+” rating in a report on Tuesday, August 6th. BidaskClub raised shares of BIO-TECHNE from a “sell” rating to a “hold” rating in a report on Tuesday, September 17th. ValuEngine raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research cut shares of BIO-TECHNE from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $240.00 price objective (up previously from $230.00) on shares of BIO-TECHNE in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. BIO-TECHNE presently has a consensus rating of “Hold” and an average target price of $212.83.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

See Also: What are momentum indicators and what do they show?

Dividend History for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Christopher R. Pizzi Sells 8,379 Shares of Cross Country Healthcare, Inc.  Stock
Christopher R. Pizzi Sells 8,379 Shares of Cross Country Healthcare, Inc. Stock
Joao V. Faria Sells 16,988 Shares of Eaton Co. PLC  Stock
Joao V. Faria Sells 16,988 Shares of Eaton Co. PLC Stock
Zacks Investment Research Downgrades Stellus Capital Investment  to Hold
Zacks Investment Research Downgrades Stellus Capital Investment to Hold
Lanxess  Given a €55.00 Price Target at Nord/LB
Lanxess Given a €55.00 Price Target at Nord/LB
Tyson Foods  PT Raised to $98.00 at BMO Capital Markets
Tyson Foods PT Raised to $98.00 at BMO Capital Markets
Shore Capital Reiterates “House Stock” Rating for Arbuthnot Banking Group
Shore Capital Reiterates “House Stock” Rating for Arbuthnot Banking Group


© 2006-2019 Ticker Report